Stockreport

Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification [Yahoo! Finance]

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF This article first appeared on GuruFocus R&D Expense: $18.4 million in Q4 2025, down from $19.8 million in Q4 2024. G&A Expense: $10.5 million in Q4 2025, up from $ [Read more]